Treatment potential for immunotherapy-induced cytokine release syndrome
Drug Discovery World
JANUARY 18, 2024
Poolbeg Pharma, a biopharmaceutical company focused on the development and commercialisation of medicines targeting diseases with a high unmet medical need, has announced promising in vivo results for POLB 001 in addressing cancer immunotherapy-induced cytokine release syndrome (CRS). million cases of cancer by 2030 1,2.
Let's personalize your content